Dr. Edgar Diaz-Cruz, in the Department of Pharmaceutical, Social & Administrative Sciences, recently had an abstract accepted for presentation at the 2013 San Antonio Brest Cancer Symposium. The work is titled “Effect of letrozole is superior to tamoxifen in limiting preneoplasia in both ERα and aromatase over-expressing mice.” As lead investigator, Cruz and his team determined the impact of letrozole was greater than tamoxifen in reducing prevalence of mammary gland preneoplasia in both ERα and aromatase over-expressing mice. These results suggest that letrozole should be considered as a chemo-preventive agent based on individual estrogen signaling prognostic factors.
